MaxLinear Is Maintained at Buy by Benchmark
Benchmark Co. Maintains MaxLinear(MXL.US) With Buy Rating, Raises Target Price to $28
Maxlinear's Promising Outlook: Buy Rating Driven by AI Growth and Market Resilience
Express News | Maxlinear Inc : Benchmark Raises Target Price to $28 From $22
MaxLinear (NASDAQ:MXL) Three-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Jumps 28% This Past Week
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
MaxLinear (NASDAQ:MXL) Shareholders Are up 8.8% This Past Week, but Still in the Red Over the Last Year
